RODRIGO BUENO DE OLIVEIRA

(Fonte: Lattes)
Índice h a partir de 2011
10
Projetos de Pesquisa
Unidades Organizacionais
LIM/16 - Laboratório de Fisiopatologia Renal, Hospital das Clínicas, Faculdade de Medicina

Resultados de Busca

Agora exibindo 1 - 4 de 4
  • article 40 Citação(ões) na Scopus
    Disturbances of Wnt/beta-catenin pathway and energy metabolism in early CKD: effect of phosphate binders
    (2013) OLIVEIRA, Rodrigo B. de; GRACIOLLI, Fabiana G.; REIS, Luciene M. dos; CANCELA, Ana L. E.; CUPPARI, Lilian; CANZIANI, Maria E.; CARVALHO, Aluizio B.; JORGETTI, Vanda; MOYSES, Rosa M. A.
    Mineral bone disorder (MBD) is an early complication of chronic kidney disease (CKD), with complex interactions in the bonekidneyenergy axis. These events lead to impaired bone remodelling, which in turn is associated with cardiovascular disease. Recently, we reported on a positive effect of phosphate binder treatment on bone remodelling markers and a reduction in serum FGF-23 levels in predialysis-CKD patients. The goal of the present study of this trial was to examine the effects of phosphate binders on energy-regulating hormones and Wnt pathway. In this present post hoc analysis of the above randomized, open-label, 8-week trial, which compared the effects of increasing doses of sevelamer-HCl or calcium acetate on various CKD-MBD parameters in 40 normophosphatemic CKD Stage 34 patients, we measured serum sclerostin, Dickkopf-1, leptin, adiponectin and serotonin concentrations. Serum sclerostin, Dickkopf-1 and leptin were elevated at baseline despite normal calcium, phosphorus levels and daily urinary phosphorus excretion. There were significant and positive correlations between sclerostin and FGF-23, as well between leptin and Dickkopf-1. Treatment with both phosphate binders led to a significant decrease in phosphate overload. However, sevelamer-HCl, but not with calcium acetate, led to a significant decrease in serum FGF-23, sclerostin and leptin, and to a significant increase in bone alkaline phosphatase levels. Early stages of CKD are associated with an impairment of the Wnt pathway, as reflected by elevated sclerostin, and a dysregulation of energy-regulating hormones. Many of these disturbances can be ameliorated by phosphate binder treatment, more with sevelamer-HCl than with calcium acetate.
  • conferenceObject
    PARATHYROIDECTOMY MAY IMPAIR PHYSIOLOGIC SYSTEMIC VASOCONSTRICTION AFTER HEMODIALYSIS PROCEDURE
    (2014) FREITAS, Geraldo R.; SILVA, Vitor B.; ABENSUR, Hugo; LUDERS, Claudio; PEREIRA, Benedito J.; CASTRO, Manuel C. M.; OLIVERIRA, Rodrigo B.; MOYSES, Rosa M. A.; ELIAS, Rosilene M.; SILVA, Bruno C.
  • conferenceObject
    EFFECTS OF PYROPHOSPHATE DELIVERY IN A PERITONEAL DIALYSIS SOLUTION ON BONE TISSUE OF APOLIPOPROTEIN-E KNOCKOUT MICE WITH CHRONIC KIDNEY DISEASE
    (2014) BARRETO, Fellype C.; OLIVEIRA, Rodrigo B. De; BENCHITRIT, Joyce; LOUVET, Loic; REZG, Raja; POIROT, Sabrina; JORGETTI, Vanda; DRUEEKE, Tilman B.; RISER, Bruce L.; MASSY, Ziad A.
  • conferenceObject
    THE CLINICAL IMPACT OF TOTAL PARATHYROIDECTOMY WITH AUTO TRANSPLANTATION IN REFRACTORY SECONDARY HYPERPARATHYROIDISM
    (2015) ALBUQUERQUE, Roxana F. C. de; MARTIN, Rita C.; MASSONI, Ledo; NASCIMENTO, Climerio do; ARAP, Sergio S.; MONTENEGRO, Fabio L. M.; MOYSES, Rosa M. A.; JORGETTI, Vanda; OLIVEIRA, Rodrigo B. de